Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2007 1
2008 1
2010 1
2011 1
2013 2
2017 2
2018 2
2019 2
2020 3
2021 3
2022 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
The hepatic first-pass metabolism of problematic drugs.
Lalka D, Griffith RK, Cronenberger CL. Lalka D, et al. Among authors: cronenberger cl. J Clin Pharmacol. 1993 Jul;33(7):657-69. doi: 10.1002/j.1552-4604.1993.tb04720.x. J Clin Pharmacol. 1993. PMID: 8366191 Review.
How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential.
Kraynov E, Martin SW, Hurst S, Fahmi OA, Dowty M, Cronenberger C, Loi CM, Kuang B, Fields O, Fountain S, Awwad M, Wang D. Kraynov E, et al. Among authors: cronenberger c. Drug Metab Dispos. 2011 Oct;39(10):1779-83. doi: 10.1124/dmd.111.040808. Epub 2011 Jul 18. Drug Metab Dispos. 2011. PMID: 21768274 Review.
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy.
Landen JW, Cohen S, Billing CB Jr, Cronenberger C, Styren S, Burstein AH, Sattler C, Lee JH, Jack CR Jr, Kantarci K, Schwartz PF, Duggan WT, Zhao Q, Sprenger K, Bednar MM, Binneman B. Landen JW, et al. Among authors: cronenberger c. Alzheimers Dement (N Y). 2017 May 10;3(3):339-347. doi: 10.1016/j.trci.2017.04.003. eCollection 2017 Sep. Alzheimers Dement (N Y). 2017. PMID: 29067341 Free PMC article.
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study.
Landen JW, Andreasen N, Cronenberger CL, Schwartz PF, Börjesson-Hanson A, Östlund H, Sattler CA, Binneman B, Bednar MM. Landen JW, et al. Among authors: cronenberger cl. Alzheimers Dement (N Y). 2017 Jun 8;3(3):393-401. doi: 10.1016/j.trci.2017.05.003. eCollection 2017 Sep. Alzheimers Dement (N Y). 2017. PMID: 29067345 Free PMC article.
Randomized, Open-Label, Single-Dose, Parallel-Group Pharmacokinetic Study of PF-06410293 (adalimumab-afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects.
Cox DS, Alvarez DF, Bock AE, Cronenberger CL. Cox DS, et al. Among authors: cronenberger cl. Clin Pharmacol Drug Dev. 2021 Oct;10(10):1166-1173. doi: 10.1002/cpdd.939. Epub 2021 Mar 25. Clin Pharmacol Drug Dev. 2021. PMID: 33765358 Free PMC article. Clinical Trial.
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
Fleischmann RM, Alvarez DF, Bock AE, Cronenberger C, Vranic I, Zhang W, Alten R. Fleischmann RM, et al. Among authors: cronenberger c. Arthritis Res Ther. 2021 Sep 25;23(1):248. doi: 10.1186/s13075-021-02626-4. Arthritis Res Ther. 2021. PMID: 34563243 Free PMC article. Clinical Trial.
18 results